Copyright and usage guidelines 3
Introduction 4
Methodology 7
Data collection 7
Sample source 7
Respondents 7
Practice type 7
Definition given to respondents 7
Executive summary 9
Familiarity 9
Prescribing likelihood 9
Pricing 9
DAW clause 9
Clinical development 10
Familiarity with biosimilars 11
Biosimilar familiarity 12
Prescribing and pricing 13
Medicine identification 14
Likelihood of prescribing a recently approved biosimilar 15
Discount required for physician recommendation 16
Switching and DAW preference 17
Importance of being notified of pharmacist decision to dispense alternative biologic … 18
Opinion on EU ban on pharmacy-level substitution 19
Percent of expected biologic prescriptions to be written with a DAW clause 20
Likelihood to use DAW clause 21
Preferred clinical testing for biosimilars 22
More concerned about safety or efficacy 23
Demographics 24
Job position 25
Practice type 26
Medical specialty 27
Board certified 27
Years in practice 28
Patients per week 28
Number of physicians at practice 28
Number of PAs at practice 28
Number of NPs at practice 28
Office location by State 29
Practice setting 30
About Industry Standard Research 31